Pds Biotechnology Corp Stock Price Prediction
| PDSB Stock | USD 2.20 0.17 8.37% |
Oversold Vs Overbought
51
Oversold | Overbought |
EPS Estimate Next Quarter (0.33) | EPS Estimate Current Year (1.15) | EPS Estimate Next Year (1.40) | Wall Street Target Price 11.9 | EPS Estimate Current Quarter (0.28) |
Using PDS Biotechnology hype-based prediction, you can estimate the value of PDS Biotechnology Corp from the perspective of PDS Biotechnology response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in PDS Biotechnology to buy its stock at a price that has no basis in reality. In that case, they are not buying PDS because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
PDS Biotechnology after-hype prediction price | USD 2.12 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
PDS |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of PDS Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
PDS Biotechnology After-Hype Price Prediction Density Analysis
As far as predicting the price of PDS Biotechnology at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in PDS Biotechnology or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of PDS Biotechnology, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
PDS Biotechnology Estimiated After-Hype Price Volatility
In the context of predicting PDS Biotechnology's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on PDS Biotechnology's historical news coverage. PDS Biotechnology's after-hype downside and upside margins for the prediction period are 0.11 and 7.00, respectively. We have considered PDS Biotechnology's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
PDS Biotechnology is moderately volatile at this time. Analysis and calculation of next after-hype price of PDS Biotechnology Corp is based on 3 months time horizon.
PDS Biotechnology Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as PDS Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading PDS Biotechnology backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with PDS Biotechnology, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.46 | 4.88 | 0.07 | 0.00 | 10 Events / Month | 9 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.20 | 2.12 | 3.64 |
|
PDS Biotechnology Hype Timeline
PDS Biotechnology Corp is at this time traded for 2.20. The entity has historical hype elasticity of -0.07, and average elasticity to hype of competition of 0.0. PDS is projected to decline in value after the next headline, with the price expected to drop to 2.12. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -3.64%, whereas the daily expected return is at this time at -0.46%. The volatility of related hype on PDS Biotechnology is about 83657.14%, with the expected price after the next announcement by competition of 2.20. The book value of the company was at this time reported as 0.79. The company recorded a loss per share of 1.17. PDS Biotechnology Corp last dividend was issued on the 18th of March 2019. The entity had 1:20 split on the 18th of March 2019. Given the investment horizon of 90 days the next projected press release will be in about 10 days. Check out PDS Biotechnology Basic Forecasting Models to cross-verify your projections.PDS Biotechnology Related Hype Analysis
Having access to credible news sources related to PDS Biotechnology's direct competition is more important than ever and may enhance your ability to predict PDS Biotechnology's future price movements. Getting to know how PDS Biotechnology's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how PDS Biotechnology may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| MREO | Mereo BioPharma Group | 0.02 | 7 per month | 0.00 | (0.10) | 5.14 | (5.79) | 19.32 | |
| TERN | Terns Pharmaceuticals | (0.02) | 10 per month | 0.00 | (0.08) | 5.68 | (5.96) | 34.09 | |
| INZY | Inozyme Pharma | (0.32) | 7 per month | 0.00 | (0.26) | 5.68 | (7.92) | 16.62 | |
| HOOK | Hookipa Pharma | (0.18) | 6 per month | 0.00 | (0.29) | 4.05 | (6.67) | 15.72 | |
| EFTR | Effector Therapeutics | (0.06) | 4 per month | 0.00 | (0.31) | 8.70 | (27.78) | 88.91 | |
| ENVB | Enveric Biosciences | 0.08 | 5 per month | 0.00 | (0.16) | 6.25 | (7.50) | 28.33 | |
| CWBR | CohBar Inc | 0.07 | 3 per month | 5.34 | 0.08 | 5.73 | (5.59) | 250.97 | |
| OCEA | Ocean Biomedical | 0.01 | 2 per month | 0.00 | (0.12) | 7.46 | (6.93) | 28.33 | |
| AVRO | AVROBIO | 0.05 | 5 per month | 1.89 | 0.02 | 4.11 | (3.17) | 14.20 | |
| XFOR | X4 Pharmaceuticals | 0.00 | 8 per month | 0.00 | (0.07) | 6.45 | (10.61) | 62.35 | |
| DAWN | Day One Biopharmaceuticals | 0.27 | 11 per month | 2.79 | (0.04) | 3.84 | (3.69) | 11.44 | |
| ELEV | Elevation Oncology | 0.01 | 10 per month | 0.00 | (0.11) | 5.77 | (8.22) | 22.21 |
PDS Biotechnology Additional Predictive Modules
Most predictive techniques to examine PDS price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for PDS using various technical indicators. When you analyze PDS charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About PDS Biotechnology Predictive Indicators
The successful prediction of PDS Biotechnology stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as PDS Biotechnology Corp, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of PDS Biotechnology based on analysis of PDS Biotechnology hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to PDS Biotechnology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to PDS Biotechnology's related companies. | 2023 | 2024 (projected) | Net Debt To EBITDA | 0.82 | 0.78 | Intangibles To Total Assets | 4.55E-4 | 3.9E-4 |
Story Coverage note for PDS Biotechnology
The number of cover stories for PDS Biotechnology depends on current market conditions and PDS Biotechnology's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that PDS Biotechnology is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about PDS Biotechnology's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
PDS Biotechnology Short Properties
PDS Biotechnology's future price predictability will typically decrease when PDS Biotechnology's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of PDS Biotechnology Corp often depends not only on the future outlook of the potential PDS Biotechnology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. PDS Biotechnology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 31 M | |
| Cash And Short Term Investments | 56.6 M |
Complementary Tools for PDS Stock analysis
When running PDS Biotechnology's price analysis, check to measure PDS Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PDS Biotechnology is operating at the current time. Most of PDS Biotechnology's value examination focuses on studying past and present price action to predict the probability of PDS Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PDS Biotechnology's price. Additionally, you may evaluate how the addition of PDS Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |